ABSTRACT
Background The neuroanatomy of hyperactive neuropsychiatric symptoms (NPS) is poorly understood, and it is unclear whether these symptoms result from the same pathogenic processes responsible for cognitive decline or if they have an independent etiology to the neurodegeneration due to Alzheimer’s disease (AD).
Objective We aim to investigate how the severity of hyperactive NPS (i.e., agitation, disinhibition, and irritability) can impact brain structures at different stages of cognitive decline.
Methods Neuropsychiatric and 3T MRI data from 223 cognitively normal (CN) participants, 367 participants with mild cognitive impairment (MCI) and 175 participants with AD were extracted from the Alzheimer Disease Neuroimaging Initiative (ADNI) database. Statistical analyses based on the general linear model (GLM) were performed to define the effects of neuropsychiatric variables on brain structures in a two-by-two comparison (AD-MCI, CN-MCI and CN-AD). Linear regression analysis was also performed to investigate cortical changes as a function of NPS severity.
Results In the AD group, the frontal dorsolateral is the most influenced region receiving an impact from more severe agitation, disinhibition and irritability. In AD, agitation and irritability influence some temporal inferior and parietal superior regions. Furthermore, severe disinhibition seems to have a stronger influence on CN participants compared to the other two groups, particularly in the occipital lingual, frontal middle rostral and frontal pars triangularis regions.
Conclusion Our study shows that hyperactive NPS influence differently the brain morphology at different stages of cognitive performance. This might imply that their severity should be evaluated in relation to results of cognitive evaluations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a research bursary from NiEmoLab to Lyna El Haffaf, a doctoral research scholarship Centre de Recherche de l'Institut Universitaire de Geriatrie Montreal (CRIUGM)-Volet B in collaboration with NiEmoLab and a Faculty of Medicine of the University of Montreal merit scholarship in collaboration with NiEmoLab given to Lucas Ronat, as well as funding from the Parkinson Canada-Parkinson Quebec (2018-00355); IUGM Foundation; Fonds de Recherche du Quebec Sante; Lemaire Foundation given to Alexandru Hanganu.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All data are available on the ADNI websites upon demand (http://adni.loni.usc.edu/data-samples/access-data/).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Alzheimer’s Disease Neuroimaging Initiative
# Data used in preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf
Data Availability
All data produced in the present work are contained in the manuscript.
Abbreviations
- ADNI
- Alzheimer’s Disease Neuroimaging Initiative;
- AD
- Alzheimer’s Disease;
- CN
- Cognitively Normal;
- MCI
- Mild Cognitive Impairment;
- GLM
- General Linear Model;
- NPI
- Neuropsychiatric Inventory;
- NPS
- Neuropsychiatric Symptoms.
